A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3

With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations,...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Fouchardière, Christelle, Gamradt, Pia, Chabaud, Sylvie, Raddaz, Maxime, Blanc, Ellen, Msika, Olivier, Treilleux, Isabelle, Bachy, Sophie, Cattey-Javouhey, Anne, Guibert, Pierre, Sarabi, Matthieu, Rochefort, Pauline, Funk-Debleds, Pamela, Coutzac, Clélia, Ray-Coquard, Isabelle, Peyrat, Patrice, Meeus, Pierre, Rivoire, Michel, Dupré, Aurélien, Hennino, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025577/
https://www.ncbi.nlm.nih.gov/pubmed/35455739
http://dx.doi.org/10.3390/jpm12040623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025577/
https://www.ncbi.nlm.nih.gov/pubmed/35455739
http://dx.doi.org/10.3390/jpm12040623

Ejemplares similares